Article thumbnail

Subunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase

By Jessica Radzio and Nicolas Sluis-Cremer
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3168420
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1992). 5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science
  2. (1999). A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell
  3. (2008). Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3’-azido3’-deoxythymidine through both RNase H-dependent and -independent mechanisms.
  4. (2010). E: Antiretroviral drugs. Curr Opin Pharmacol
  5. (2001). E: Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA.
  6. (2008). Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility. AIDS Rev
  7. (2009). Götte M: HIV-1 reverse transcriptase can simultaneously engage its DNA/RNA substrate at both DNA polymerase and RNase H active sites: implications for RNase H inhibition.
  8. (2010). Götte M: N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.
  9. (1990). Grüninger-Leitch F: Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography.
  10. (1991). Restle T: Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo.
  11. (2010). Sarafianos SG: The N348I mutation at the connection subdomain of HIV1 reverse transcriptase decreases binding to nevirapine.
  12. (1986). Sarngadharan MG: Characterization of highly immunogenic p66/ p51 as the reverse transcriptase of HTLV-III/LAV. Science
  13. (2007). Sluis-Cremer N: Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT.
  14. (2008). Sluis-Cremer N: Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Mol Pharmacol
  15. (2008). Sluis-Cremer N: Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry
  16. (2010). Sluis-Cremer N: N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations. AIDS
  17. TA: Crystal structure at
  18. (2007). Tachedjian G: N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med
  19. (2009). The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.
  20. (2010). VK: A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
  21. (2007). Yang W: Structure of human RNase H1 complexed with an RNA/DNA hybrid: insight into HIV reverse transcription. Mol Cell